Catalyst Pharmaceuticals (CPRX) Tax Provisions (2019 - 2026)

Catalyst Pharmaceuticals' Tax Provisions history runs 8 years deep, the most recent figure standing at $20.5 million for Q1 2026.

• Quarterly Tax Provisions rose 40.87% year-over-year to $20.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $65.5 million (up 7.16% YoY) and the FY2025 annual result came in at $59.5 million, up 13.68% from the prior year.
• Tax Provisions was $20.5 million for Q1 2026 at Catalyst Pharmaceuticals, up from $9.6 million in the prior quarter.
• Across five years, Tax Provisions topped out at $29.7 million in Q4 2023 and bottomed at -$7.3 million in Q3 2023.
• A 5-year average of $11.5 million and a median of $10.8 million in 2023 frame the typical range for Tax Provisions.
• Peak annual rise in Tax Provisions reached 293.63% in 2023, while the deepest fall reached 322.68% in 2023.
• Catalyst Pharmaceuticals' Tax Provisions stood at $7.5 million in 2022, then surged by 293.63% to $29.7 million in 2023, then plunged by 38.5% to $18.2 million in 2024, then tumbled by 47.65% to $9.6 million in 2025, then surged by 114.56% to $20.5 million in 2026.
• Business Quant data shows CPRX's Tax Provisions at $20.5 million in Q1 2026, $9.6 million in Q4 2025, and $18.3 million in Q3 2025.